Life Science News

RSS

New mechanism to enhance precision in cancer drug development

Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could affect how certain cancer drugs are developed.

15 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026

ANU researchers map hidden cellular networks to better understand diseases

A new nanoscopy technique developed at The Australian National University (ANU) has uncovered hidden networks used for communication between cells, opening new ways to understand human diseases.

15 May 2026

How exercise influences cancer cell viability

This interview uncovers how exercise may reduce cancer cell viability, with insights into adipose interactions and innovative 3D culture systems.

From Promega Corporation 15 May 2026

Rocket Science Health validates targeted olfactory-cleft deposition in non-human primates ahead of the 4th Nasal Formulation & Delivery Summit

As the pace of modern drug discovery accelerates, the industry is increasingly recognizing that a breakthrough molecule is only as effective as its ability to reach the target site.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

Fujitsu and IBM Japan formalize collaboration in healthcare sector

Fujitsu Limited and IBM Japan, Ltd. today announced the formalization of a collaboration within the healthcare domain, building on considerations first announced in September 2025.

From Fujitsu Limited 15 May 2026

Study identifies breakthrough drug combination for early-stage Peyronie’s

Combining two widely prescribed drug classes could provide the first effective treatment for early-stage Peyronie's disease, according to a new study published in The Journal of Sexual Medicine.

15 May 2026

Genetic mapping in wastewater sets a new standard for pathogen surveillance

Tracking the genetic diversity of SARS-CoV-2 in wastewater, rather than just viral abundance, dramatically improves the ability to monitor and predict COVID-19 outbreaks, researchers report. Their study suggests that the new approach to wastewater pathogen surveillance could serve as a powerful predictive tool for public health, providing earlier and more accurate insight into emerging waves of infection.

15 May 2026

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

New technology reveals how RNA shapes influence protein production and stability

Researchers from A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new method, called 'sm-PORE-cupine', to study individual RNA molecules and reveal how their structures influence gene regulation, a fundamental process that affects how cells function in health and disease.

15 May 2026

Brain immune cells found to regulate anxiety and grooming behaviors

A study led by a University of Louisville School of Medicine pediatrics and child neurology researcher reveals how a specific signaling mechanism in microglia, the brain's immune cell, can regulate anxiety and grooming behaviors. These behaviors are core symptoms of autism and obsessive-compulsive spectrum disorders.

14 May 2026

Clinical trial challenges long held beliefs about treating brittle bone disease

Increasing bone density in patients with a rare genetic condition that causes bones to break easily does not prevent fractures, a large clinical trial has found.

14 May 2026

Stanford scientists map the molecular diversity of different global populations

Researchers at the Stanford School of Medicine have found that ethnicity and geography may influence human molecular makeup - from metabolism and immunity to gut microbiota and biological aging.

14 May 2026

Study reveals how brain cells process vision amidst thousands of synaptic inputs

Even in the primary visual cortex, a brain region named for its specialized role in processing basic features of what the eyes see, not every neuron ends up answering the call to process properties of visual input. Maybe that's because each neuron receives a wide variety of inputs via thousands of circuit connections, or "synapses," and has to opt to respond to the visual information vs. something else.

14 May 2026

A breakthrough molecular discovery could neutralize gluten and protect coeliac patients

A research project led by the Institute for Research in Nutrition and Food Safety (INSA) and the Faculty of Pharmacy and Food Sciences at the University of Barcelona, together with the Molecular Biology Institute of Barcelona (IBMB) of the CSIC (which stands for Consejo Superior de Investigaciones Científicas), has successfully designed and tested a gluten-degrading molecule that is a promising ally in the management of coeliac disease, an autoimmune disease whose symptoms are triggered by the consumption of gluten and other prolamins found in cereals.

14 May 2026

New non invasive way to diagnose childhood epilepsy through blood sugar patterns

A study published in Engineering has demonstrated that the N-glycome of serum-derived extracellular vesicles (EVs) can serve as a non-invasive biosignature for the diagnosis and classification of childhood epilepsy, offering a new tool for precision and longitudinal monitoring in clinical settings.

14 May 2026

Solving the mystery of ALS survival differences with new biological insights

Patients with ALS, or Lou Gehrig's disease, live an average of only three years after symptoms begin, though some can survive closer to 10 years. What drives these differences in survival has remained a mystery.

14 May 2026

New imaging technique maps 38000 liver cells to solve fibrosis

The liver is often called a "silent organ," as it can sustain significant damage without obvious symptoms. But when injury is prolonged, whether from alcohol, poor diet, or chronic hepatitis virus infection, it triggers fibrosis: a progressive hardening and scarring of liver tissue.

14 May 2026

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

From Society for Laboratory Automation and Screening (SLAS) 13 May 2026

Base editing approach repairs deadly Dravet syndrome mutation in mice

Gene editing can repair a DNA error in mice that causes Dravet syndrome, a rare, incurable, and potentially deadly form of childhood epilepsy. After the edit, the mice have far fewer seizures and live much longer.

13 May 2026